Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Clinical pharmacology and therapy

• Publication date

  1999-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0009-9236(99)70051-2PMID 10430107
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.

  2003cited by this paper
• Saquinavir

  1998cited by this paper
• Antiretroviral therapy for patients with HIV disease.

  1998cited by this paper
• Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors.

  1998cited by this paper
• Itraconazole greatly increases plasma concentrations and effects of felodipine

  1997cited by this paper
• Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole

  1997cited by this paper
• Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease.

  1997cited by this paper
• The Effect of the Systemic Antimycotics, Itraconazole and Fluconazole, on the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Midazolam

  1996cited by this paper
• Interaction between midazolam and clarithromycin: comparison with azithromycin.

  1996cited by this paper
• The effect of ingestion time interval on the interaction between itraconazole and triazolam

  1996cited by this paper
• Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

  1995cited by this paper
• Midazolam is metabolized by at least three different cytochrome P450 enzymes.

  1994cited by this paper
• Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.

  1994cited by this paper
• Dose of midazolam should be reduced during diltiazem and verapamil treatments.

  1994cited by this paper
• A potentially hazardous interaction between erythromycin and midazolam.

  1993cited by this paper
• Determination of Midazolam and Its α‐Hydroxy Metabolite in Human Plasma and Urine by High‐Performance Liquid Chromatography

  1993cited by this paper
• Pencil and paper tests--sensitivity to psychotropic drugs.

  1984cited by this paper
• Pharmacokinetics and bioavailability of midazolam in man.

  1983cited by this paper
• Midazolam kinetics

  1981cited by this paper
• Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects—A review

  1976cited by this paper
• The use of analogue scales in rating subjective feelings

  1974cited by this paper
• Measurement of Recovery from Outpatient General Anaesthesia with a Simple Ocular Test

  1970cited by this paper

• Prediction of Pharmacokinetics for CYP3A4-Metabolized Drugs in Pediatrics and Geriatrics Using Dynamic Age-Dependent Physiologically Based Pharmacokinetic Models

  2025influential citation
• Optimization of In Vitro CYP3A4 TDI Assay Conditions and Use of Derived Parameters for Clinical DDI Risk Assessment Using Static and Dynamic Models

  2025cites this paper
• Perioperative Medication Management

  2024cites this paper
• Quantitatively Predicting Effects of Exercise on Pharmacokinetics of Drugs Using a Physiologically Based Pharmacokinetic Model

  2024cites this paper
• Optimising the oral midazolam dose for premedication in people with intellectual disabilities and/or autism spectrum disorder.

  2024cites this paper
• A literature review of liver function test elevations in rifampin drug–drug interaction studies

  2022cites this paper
• Sedation and HIV medication

  2022cites this paper
• HIV Infection and Related Mental Disorders

  2021cites this paper
• Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for Inactivation Rate Constants

  2020cites this paper
• The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drug–Drug Interactions

  2020cites this paper
• In vitro–in vivo extrapolation of metabolic clearance using human liver microsomes: factors showing variability and their normalization

  2020cites this paper
• Pharmacokinetics and Pharmacology of Drugs Used in Children

  2019cites this paper
• Progress in the Consideration of Possible Sex Differences in Drug Interaction Studies.

  2019cites this paper
• Preoperative Evaluation, Premedication, and Induction of Anesthesia

  2019cites this paper
• An update on the potential role of intestinal first-pass metabolism for the prediction of drug–drug interactions: the role of PBPK modeling

  2018cites this paper
• [Quantitative Prediction of Drug-Drug Interaction Caused by CYP Inhibition and Induction from In Vivo Data and Its Application in Daily Clinical Practices-Proposal for the Pharmacokinetic Interaction Significance Classification System (PISCS)].

  2018cites this paper
• Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals

  2018cites this paper
• Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications

  2018cites this paper
• Dosing Recommendations for Quetiapine When Coadministered With HIV Protease Inhibitors

  2018cites this paper
• The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer

  2017cites this paper
• Unequivocal evidence supporting the segregated flow intestinal model that discriminates intestine versus liver first-pass removal with PBPK modeling.

  2017cites this paper
• Clinically Significant Interactions with Anesthetic Agents

  2016cites this paper
• [Severe or life-threatening interactions between antiretrovirals and non-HIV drugs].

  2015cites this paper
• Drug-drug interactions: antiretroviral drugs and recreational drugs.

  2015cites this paper
• A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products

  2015cites this paper
• Are Physiologically Based Pharmacokinetic Models Reporting the Right Cmax? Central Venous Versus Peripheral Sampling Site

  2015cites this paper
• nteracciones graves o potencialmente letales entre antirretrovirales otros medicamentos

  2015cites this paper
• APPLICATIONS OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELLING TO PREDICTION OF THE LIKELIHOOD OF METABOLIC DRUG INTERACTIONS IN PAEDIATRIC POPULATION AND STUDYING DISPARITIES IN PHARMACOKINETICS BETWEEN CHILDREN AND ADULTS

  2014cites this paper
• DRUG-DRUG INTERACTIONS - FROM KNOWLEDGE BASE TO CLINICAL IMPACT

  2014cites this paper
• Clinical relevance : An update on the drug interactions relating to midazolam are worthy of scrutiny as its use becomes more commonplace in clinical practice

  2014cites this paper
• The Importance of Villous Physiology and Morphology in Mechanistic Physiologically-Based Pharmacokinetic Models

  2014cites this paper
• Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat

  2014cites this paper
• Midazolam and drug-drug interactions in dental conscious sedation.

  2014cites this paper
• Assessment of Intestinal Availability (FG) of Substrate Drugs of Cytochrome P450s by Analyzing Changes in Pharmacokinetic Properties Caused by Drug–Drug Interactions

  2014cites this paper
• A Re-evaluation and Validation of Ontogeny Functions for Cytochrome P450 1A2 and 3A4 Based on In Vivo Data

  2014cites this paper
• Application of Clearance Theory to the Evaluation and Provision of Drug Information on Renal Dysfunction and Drug-drug Interactions

  2013cites this paper
• Authors' Reply

  2013cites this paper
• The effect of ticagrelor on the metabolism of midazolam in healthy volunteers.

  2013cites this paper
• A simplified approach to predict CYP3A-mediated drug–drug interactions at early drug discovery: validation with clinical data

  2013cites this paper
• Safety of midazolam for sedation of HIV‐positive patients undergoing colonoscopy

  2013cites this paper
• Clinical implications and management of drug-drug interactions between antiretroviral agents and psychotropic medications

  2013cites this paper
• Drug Interactions with Benzodiazepines: Epidemiologic Correlates with Other CNS Depressants and In Vitro Correlates with Inhibitors and Inducers of Cytochrome P450 3A4

  2012cites this paper
• Role of Inflammation in Metabolism and Hepatotoxicity of Prototypical Drugs

  2012cites this paper
• Risk Assessment of Mechanism-Based Inactivation in Drug-Drug Interactions

  2012cites this paper
• Loss of orally administered drugs in GI tract.

  2012cites this paper
• CYP3A‐dependent drug metabolism is reduced in bacterial inflammation in mice

  2012cites this paper
• Severe Prolonged Sedation Associated with Coadministration of Protease Inhibitors and Intravenous Midazolam During Bronchoscopy

  2012cites this paper
• Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction

  2011cites this paper
• Enhancement of GABAergic Activity: Neuropharmacological Effects of Benzodiazepines and Therapeutic Use in Anesthesiology

  2011cites this paper
• Prediction of CYP3A-Mediated Drug-Drug Interactions Using Human Hepatocytes Suspended in Human Plasma

  2011cites this paper
• Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals.

  2011cites this paper
• Effects of multiple doses of clarithromycin on the pharmacokinetics of laropiprant in healthy subjects.

  2011cites this paper
• Itraconazole, a P‐Glycoprotein and CYP3A4 Inhibitor, Markedly Raises the Plasma Concentrations and Enhances the Renin‐Inhibiting Effect of Aliskiren

  2011cites this paper
• Assessment of algorithms for the prediction of metabolic drug-drug interactions

  2011cites this paper
• Confidence Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP3A Inhibitors

  2010cites this paper
• Azole antimycotics and drug interactions in the perioperative period

  2010cites this paper
• Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions.

  2010cites this paper
• Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.

  2010influential citation
• Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information.

  2010cites this paper
• In vitro techniques to study drug-drug interactions of drug metabolism: Cytochrome P450

  2010cites this paper
• Impact of Physiological Determinants: Flow, Binding, Transporters and Enzymes on Organ and Total Body Clearances

  2010cites this paper
• Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP 3 A Inhibitors

  2010cites this paper
• Anaesthetic considerations of the HIV-infected patients

  2009cites this paper
• Factors that restrict intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): Part II. Role of metabolic enzymes in the intestinal mucosa.

  2009cites this paper
• Effect of Saquinavir‐Ritonavir on Cytochrome P450 3A4 Activity in Healthy Volunteers Using Midazolam as a Probe

  2009cites this paper
• Evaluation of Recombinant Cytochrome P450 Enzymes as an in Vitro System for Metabolic Clearance Predictions

  2009cites this paper
• Effects of Ketoconazole and Quinidine on Pharmacokinetics of Pactimibe and Its Plasma Metabolite, R-125528, in Humans

  2008cites this paper
• Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions

  2008cites this paper
• Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice

  2008cites this paper
• Maraviroc: in vitro assessment of drug-drug interaction potential.

  2008cites this paper
• Anesthesia in HIV‐infected children

  2007cites this paper
• General Framework for the Quantitative Prediction of CYP3A4-Mediated Oral Drug Interactions Based on the AUC Increase by Coadministration of Standard Drugs

  2007cites this paper
• The role of cytochrome P450 in antiretroviral drug interactions

  2007cites this paper
• The role of cytochrome P450 in antiretroviral drug interactions.

  2007cites this paper
• Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs.

  2007cites this paper
• Complications of endoscopy.

  2007cites this paper
• Voriconazole and fluconazole increase the exposure to oral diazepam

  2007cites this paper
• Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.

  2006cites this paper
• The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions

  2006cites this paper
• Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.

  2006cites this paper
• Effect of green tea extract on expression of proteins involved in drug transport and metabolism and on the expression and secretion of the chemokine interleukin-8 in intestinal cell lines

  2006cites this paper
• Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam

  2006cites this paper
• Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children

  2006cites this paper
• Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate

  2006influential citation
• Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors

  2005cites this paper
• Mechanism-Based Inactivation of CYP 3 A by HIV Protease Inhibitors

  2005cites this paper
• JPET #93229 1 THE UTILITY OF IN VITRO CYTOCHROME P450 INHIBITION DATA IN THE PREDICTION OF DRUG-DRUG INTERACTIONS

  2005cites this paper
• Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein.

  2005cites this paper
• In vitro cytochrome P450 inhibition data and the prediction of drug‐drug interactions: Qualitative relationships, quantitative predictions, and the rank‐order approach

  2005cites this paper
• Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5

  2005cites this paper
• Reduction of Saquinavir Exposure by Coadministration of Loperamide

  2004cites this paper
• Differentiation of Gut and Hepatic First Pass Metabolism and Secretion of Saquinavir in Ported Rabbits

  2004influential citation
• BASED INACTIVATION OF CYTOCHROME P 450 3 A ( CYP 3 A ) BY HIV PROTEASE INHIBITORSa

  2004cites this paper
• PREDICTION OF CYTOCHROME P 450 3 A INHIBITION BY VERAPAMIL ENANTIOMERS AND THEIR METABOLITES

  2004influential citation
• Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.

  2004influential citation
• Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone

  2004cites this paper
• Clinically Important Drug Interactions with Intravenous Anaesthetics in Older Patients

  2003cites this paper
• Role of Intestinal Cytochromes P450 in Drug Disposition

  2003cites this paper
• Drug-drug interactions: an important negative attribute in drugs.

  2003cites this paper
• Drug Interactions Between Antiretroviral Drugs and Comedicated Agents

  2003cites this paper